ACW clinical biomarker study webcast presentation
Filed with ASX · · 46 pages · English
Sydney, 10 October 2022. Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to release the attached presentation slides relating to the positive Phase 2a clinical data from its Alzheimer’s Disease (AD) biomarker study announced this morning on the ASX platform. Webcast today at 11am AEDT Actinogen CEO Dr Steven Gourlay and CMO Professor Paul Rolan will present the slides at a webcast a
Actinogen Medical Limited on 6ix
In the deck
Story so far
Earlier from Actinogen Medical
- ACW announces positive Alzheimers Disease clinical results
- Actinogen FY22 Results - Accelerating Clinical Development
- ACW Appendix 4E and 2022 Annual Report
- ACW CEO presentation to Spark Plus Aust Equities Day
- Application for quotation of securities - ACW
Later from Actinogen Medical
- R&D tax incentive rebate received
- First patient treated in XanaCIDD Phase 2 Depression Trial
- FDA agrees to six-month Phase 2b Alzheimers Disease Trial
- Appendix 4D & Half-Year Financial Statements
- ACW AD trial amendment and Clinical Science Forum slides
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical